3 in 5 US abortions now rely on mifepristone as court weighs limits

Clinicians and health systems should watch this case closely: mifepristone is central to the most common U.S. abortion method, and any prescription restriction would ripple through telehealth workflows, shield-law practice, and patient access. The FDA's parallel review adds another layer of uncertainty for providers managing medication abortion services.

The 5th U.S. Circuit Court of Appeals heard oral arguments on September 9, 2026, in a closely watched challenge that could tighten prescribing rules for mifepristone, one component of the most common medication abortion regimen in the United States. The case, brought by Louisiana Attorney General Liz Murrill and Rosalie Markezich, is one of three pending appeals seeking to prevent providers in states with legal abortion from sending mifepristone into states that ban or restrict the procedure. The dispute sits at the intersection of FDA drug regulation, state criminal law, and the post-Dobbs geography of abortion access.

“

The case, brought by Louisiana Attorney General Liz Murrill and Rosalie Markezich, is one of three pending appeals seeking to prevent providers in states with legal abortion from sending mifepristone into states that ban or restrict the procedure.

At least 3 in 5 U.S. abortions are now obtained using a two-drug combination of mifepristone and misoprostol, making mifepristone one of the most consequential prescription drugs in the country. The plaintiffs argue current FDA rules are too loose, while the FDA says it is reviewing those very rules and that its administrative process should take precedence over court action. That agency-versus-litigation conflict is the procedural faultline running through the case.

The practical stakes are measurable. A survey conducted for the Society of Family Planning, which supports legal abortion access, estimates that between 770 and 900 women in Louisiana obtained abortions each month in 2025 by using pills prescribed online or by clinicians in other states that have shield laws intended to protect those prescribers. Louisiana bans most abortions, so cross-border telehealth prescribing has become the primary workaround for residents seeking medication abortion.

The 5th Circuit panel itself is ideologically mixed, with two judges nominated by Democratic presidents Barack Obama and Joe Biden and one nominated by Republican George W. Bush. But the broader circuit has already signaled skepticism: three prior three-judge panels and two district courts have agreed that mifepristone prescribing rules are too loose. That pattern suggests the appeals court is not operating from a blank slate and may be inclined to impose restrictions even if this particular panel is more evenly divided. The U.S. Supreme Court will almost certainly be asked to resolve the dispute, especially because multiple federal appeals and FDA rulemaking are likely to produce conflicting signals.

The political context is equally significant. The arguments arrive in a midterm election year in which President Donald Trump's anti-abortion supporters are frustrated that a legal workaround to abortion bans remains. At the same time, most voters favor legal abortion access in most cases. That tension may pressure both the administration and the courts, even as the FDA attempts to keep the issue inside agency rulemaking.